adjuvant therapy

• 

Adjuvant therapy for kidney cancer

By Sharon Deveson Kell|2023-06-23T07:53:54+00:0023 Jun 2023|Drug treatments|

Adjuvant therapy aims to reduce the risk of the cancer [...]

Read More

Comments Off on Adjuvant therapy for kidney cancer

• 

Adjuvant nivolumab plus ipilimumab for localised kidney cancer

By Sharon Deveson Kell|2023-03-20T09:50:05+00:0020 Mar 2023|Drug treatments|

In this randomised phase 3 trial, the effectiveness and safety [...]

Read More

Comments Off on Adjuvant nivolumab plus ipilimumab for localised kidney cancer

• 

Adjuvant nivolumab plus ipilimumab in localised kidney cancer

By Sharon Deveson Kell|2023-02-27T10:20:33+00:0027 Feb 2023|Drug treatments|

A recent phase 3 study called CheckMate 914 has shown [...]

Read More

Comments Off on Adjuvant nivolumab plus ipilimumab in localised kidney cancer

• 

ASCO GU 2023: Adjuvant pembrolizumab for different risks and stages of kidney cancer

By Sharon Deveson Kell|2023-02-22T09:34:55+00:0022 Feb 2023|Drug treatments|

At the American Society of Clinical Oncology Genitourinary Cancers Symposium [...]

Read More

Comments Off on ASCO GU 2023: Adjuvant pembrolizumab for different risks and stages of kidney cancer

• 

ASCO GU 2023: Patient perception of benefits and risks of adjuvant therapy for kidney cancer

By Sharon Deveson Kell|2023-02-22T09:52:33+00:0022 Feb 2023|Drug treatments|

At the American Society of Clinical Oncology Genitourinary Cancers Symposium [...]

Read More

Comments Off on ASCO GU 2023: Patient perception of benefits and risks of adjuvant therapy for kidney cancer

• 

Adjuvant pembrolizumab approved in Scotland

By Sharon Deveson Kell|2022-10-11T09:50:08+00:0011 Oct 2022|Drug treatments|

Yesterday is was announced that the Scottish Medicines Consortium (SMC) [...]

Read More

Comments Off on Adjuvant pembrolizumab approved in Scotland

• 

Adjuvant pembrolizumab approved by NICE

By Sharon Deveson Kell|2022-10-25T08:05:58+00:0026 Sep 2022|Drug treatments|

Late last week we learnt that the National Institute for [...]

Read More

Comments Off on Adjuvant pembrolizumab approved by NICE

• 

ESMO 2022: Atezolizumab as an adjuvant therapy

By Sharon Deveson Kell|2022-09-14T08:03:58+00:0012 Sep 2022|Drug treatments|

The results from the IMmotion010 study were presented at the [...]

Read More

Comments Off on ESMO 2022: Atezolizumab as an adjuvant therapy

• 

ESMO 2022: Nivolumab before and after surgery to prevent recurrence of kidney cancer

By Sharon Deveson Kell|2022-09-14T08:05:41+00:0012 Sep 2022|Drug treatments|

In this phase 3 randomised study, presented at the European [...]

Read More

Comments Off on ESMO 2022: Nivolumab before and after surgery to prevent recurrence of kidney cancer

• 

Nivolumab plus ipilimumab for localised kidney cancer

By Sharon Deveson Kell|2022-08-22T14:51:07+00:0022 Aug 2022|Drug treatments|

In a recent phase 3 clinical trial the combination of [...]

Read More

Comments Off on Nivolumab plus ipilimumab for localised kidney cancer